ROS-regulated phosphorylation of ITPKB by CAMK2G drives cisplatin resistance in ovarian cancer

Cancer Statistics, 2021

(2021) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Increased Reactive Oxygen Species–Mediated Ca 2+ /Calmodulin-Dependent Protein Kinase II Activation Contributes to Calcium Handling Abnormalities and Impaired Contraction in Barth Syndrome

(2021) Xujie Liu et al.   CIRCULATION

CaMKII Serine 280 O-GlcNAcylation Links Diabetic Hyperglycemia to Proarrhythmia

(2021) Bence Hegyi et al.   CIRCULATION RESEARCH

Challenges and Opportunities for Therapeutic Targeting of Calmodulin Kinase II in Heart

(2020) Drew Nassal et al.   Frontiers in Pharmacology

DGKA provides platinum resistance in ovarian cancer through activation of cJUN-WEE1 signaling

(2020) Jie Li et al.   CLINICAL CANCER RESEARCH

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer

(2020) Elaine Sanij et al.   Nature Communications

Mutant and wild-type isocitrate dehydrogenase 1 share enhancing mechanisms involving distinct tyrosine kinase cascades in cancer

(2019) Dong Chen et al.   Cancer Discovery

Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balance

(2019) Chaoyun Pan et al.   JOURNAL OF CLINICAL INVESTIGATION

A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy

(2019) Jessica L. Wojtaszek et al.   CELL

ROS-mediated inactivation of the PI3K/AKT pathway is involved in the antigastric cancer effects of thioredoxin reductase-1 inhibitor chaetocin

(2019) Chuangyu Wen et al.   Cell Death & Disease

MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation

(2018) Lingtao Jin et al.   CANCER CELL

Kinase-targeted cancer therapies: progress, challenges and future directions

(2018) Khushwant S. Bhullar et al.   Molecular Cancer

Kinase inhibitors: the road ahead

(2018) Fleur M. Ferguson et al.   NATURE REVIEWS DRUG DISCOVERY

C/EBPβ enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation

(2018) Dan Liu et al.   Nature Communications

DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells

(2018) Yizhou Joseph He et al.   NATURE

MLK3 phosphorylation by ERK1/2 is required for oxidative stress-induced invasion of colorectal cancer cells

(2017) A L Schroyer et al.   ONCOGENE

Ovarian cancer: beyond resistance

(2015) David Holmes   NATURE

The problem with platinum

(2015) David Holmes   NATURE

Mitochondrial Reactive Oxygen Species (ROS) and ROS-Induced ROS Release

(2014) Dmitry B. Zorov et al.   PHYSIOLOGICAL REVIEWS

CaMKII inhibitors: from research tools to therapeutic agents

(2014) Patricia Pellicena et al.   Frontiers in Pharmacology

Evaluating cell lines as tumour models by comparison of genomic profiles

(2013) Silvia Domcke et al.   Nature Communications

Molecular mechanisms of cisplatin resistance

(2011) L Galluzzi et al.   ONCOGENE

Enhancing Tumor-Specific Uptake of the Anticancer Drug Cisplatin with a Copper Chelator

(2010) Seiko Ishida et al.   CANCER CELL

Inositol 1,4,5-trisphosphate 3-kinase B controls survival and prevents anergy in B cells

(2010) Yoann Maréchal et al.   IMMUNOBIOLOGY

Inositol 1,4,5-Trisphosphate 3-Kinase B Is a Negative Regulator of BCR Signaling That Controls B Cell Selection and Tolerance Induction

(2009) A. T. Miller et al.   JOURNAL OF IMMUNOLOGY

Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth

(2009) T. Hitosugi et al.   Science Signaling